Medication options for treatment-resistant schizophrenia: Implications for global mental health financing

International Journal of Psychiatry in Clinical Practice

Volumn 10, Issue 3, 2006, Pages 213-219

  Sobhan, Tanveer ^a,c   Sobhan, Faujia Z ^a   Feldman, Jacqueline M ^b   Ryan, William G ^b  

^a Faith Regional Medical Center   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c NONE   (United States)

Author keywords

Antipsychotic combination; Community psychiatry; Treatment resistant schizophrenia

Indexed keywords

AMISULPRIDE; BENZODIAZEPINE; CARBAMAZEPINE; CELECOXIB; CLOZAPINE; CYCLOSERINE; DONEPEZIL; FLUPHENAZINE; GLYCINE; HALOPERIDOL; INDOLEACETIC ACID; LAMOTRIGINE; LITHIUM; LOXAPINE; MOOD STABILIZER; NICOTINE; OLANZAPINE; PIMOZIDE; PLACEBO; POLYUNSATURATED FATTY ACID; PROPRANOLOL DERIVATIVE; RISPERIDONE; SULPIRIDE; VALPROIC ACID;

ARTICLE; BEHAVIOR CHANGE; BRAIN DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH SERVICE; HOSPITALIZATION; HUMAN; MEDICAL PRACTICE; MENTAL HEALTH; NEUROTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHIATRIST; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM;

EID: 33748440769     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500600649960     Document Type: Article

References (50)

1. Practice Guidelines for the Treatment of Patients with Schizophrenia. 2nd ed. Am J Psychiatry 2004; 161(2 Suppl):24.
2. Conley RR, Deanna LK. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001;50(11): 898-911.
3. Brenner HD, Dencker SJ, Goldstein MJ, et al. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990;16(4):551-61.
4. Kane J, Honigfeld G, Singer J. Clozapine for treatment resistant schizophrenia: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
5. Kinon B, Kane JM, Perovish R. Influence of neuroleptic dose and class in treatment-resistant schizophrenia relapse. Presented at the 32nd Annual Meeting of the New Clinical Drug Evaluation Unit, Key Biscayne, Florida; 1992.
6. Smith E, Docherty JP. Standards of care and clinical algorithms for treating schizophrenia. Psychiatr Clin North Am 1998;21:203-20.
7. Barnes TR, McEvedy CJ. Pharmacological treatment strategies in the non-responsive schizophrenic patient. Int Clin Psychopharmacol 1996;11(Suppl 2):67-71.
8. Marder R. Antipsychotic drugs and relapse prevention. Schizophr Res 1999;35:S87-92.
9. Miller AL, Chiles JA, Chiles JK, Crimson MD. The TMAP schizophrenia algorithms. J Clin Psychiatry 1999;60: 649-57.
10. Leucht S, McGrath J, Kissling W. Lithium for schizophrenia (Cochrane Review). The Cochrane Library, issue 2. Chichester: John Wiley & Sons; 2004.
11. Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: Choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 1991;17:217-45.
12. Sculz SC, Thompson PA, Jacobs M. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. J Clin Psychiatry 1999;60:366-72.
13. Meltzer HY, Lee M, Cola P. The evolution of treatment-resistance: biologic implications. J Clin Psychopharmacol 1998;18:S5-11.
14. Simhandl C, Meszaros K. The use of carbamazepine in the treatment of schizophrenia and schizoaffective psychosis: A review. J Psychiatr Neurosci 1992;17:1-14.
15. Citrome L, Levine J, Allingham B. Changes in the use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv 2000;51: 634-8.
16. Wassef AA, Dott SG, Harris A. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J Clin Psychopharmacol 2000;20:357-61.
17. Dose M, Hellweg R, Yassouridis A. Combined treatment of schizophrenic psychosis with haloperidol and valproate. Pharmacopsychiatry 1998;31:122-5.
18. Dursun M, McIntosh D, Milliken H. Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch Gen Psychiatry 1999;56:950.
19. Wolkowitz M, Turetsky N, Rues VI. Bezodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia. Psychopharmacol Bull 1992;28:291-5.
20. Pato CN, Wolkowitz OM, Rapaport M. Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia. Psychopharmacol Bull 1989;25:263-6.
21. Meltzer HY. New drugs for the treatment of schizophrenia. Psychiatr Clin North Am 1993;16:365-85.
22. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia (Cochrane Review). The Cochrane Library, issue 2. Chichester: John Wiley & Sons; 2004.
23. Chanpattana W, Comchai Chakrabhand ML. Combined ECTand neuroleptic therapy in treatment-refractory schizophrenia: Prediction of outcome. Psych Res 2001;105:107-15.
24. Chanpattana W, Kramer BA. Acute and maintenance ECT with flupenthixol in refractory schizophrenia: Sustained improvements in psychopathology, quality of life, and social outcomes. Schizophr Res 2003;63(1-2):189-93.
25. Keks NA, Altson K, Hope J. Use of antipsychotics and adjunctive medications by an inner urban community psychiatry service. Aust NZ J Psychiatry 1999;33(6): 896-901.
26. Adesanya A, Pantelis C. Adjunctive risperidone treatment in patients with clozapine-resistant schizophrenia. Aust NZ J Psychiatry 2000;34(3):533-4.
27. Gupta S, Sonnenberg SJ, Frank B. Olanzapine augmentation of clozapine. Ann Clin Psychiatry 1998;10(3):113-5.
28. Mowerman S, Siris SG. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. Ann Clin Psychiatry 1996;8:193-7.
29. Shiloh R, Zemishlany Z, Aizenberg D. Sulpiride augmentationin people with schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled study. Br J Psychiatry 1997;171:569-73.
30. Friedman J, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol Psychiatr 1999;42(6):522-3.
31. Munro JC. Poster presented at 40th Annual Meeting of American College of Neuropsychopharmacology, December 9-13 2001, Waikoloa, Hawaii.
32. Lemer V, Chudakova B, Kravets S, Ployakova I. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: A preliminary case series report. Clin Neuropharmacol 2000;23(5):284-6.
33. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. Clin Psychiatry 1996;57:395-7.
34. Masand P. An evidence based approach to rational polypharmacy in schizophrenia. Presented at the APA Annual Meeting, San Fransisco, 17-23 May 2003.
35. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 2004;55: 165-71.
36. Muller N, Riedel M, Scheppach C. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002;159(6): 1029-34.
37. Emsley R, Oosthuizen P, Van Rensburg SJ. Clinical potential of omega-3 fatty acids in the treatment of schizophrenia. CNS Drugs 2003;17(15):1081-91.
38. Strous RD, Maayan R. DHEA augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 2003;60:133-41.
39. Wahlbeck K, Cheine MV, Gilbody S. Efficacy of beta-blocker supplementation for schizophrenia: A systematic review of randomized trials. Schizophr Res 2000;41(2): 341-7.
40. Risch SC. Poster presented at 41st Annual Meeting of American College of Neuropsychopharmacology, 8-12 December 2002, San Juan, Puerto Rico.
41. Stryjer R, Strous RD, Bar F, et al. Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clin Neuropharmacol 2003; 26(1):12-7.
42. Torrey EF. The release of the mentally ill from institutions: A well-intentional disaster. Chronicle Higher Educ 1997;13 June:14.
43. Robin EC, Bartels SJ, Mellman TA. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: Implications for State Mental Health policy. Schizophr Bull 2002;28(1):75-84.
44. Medicaid formulary policies: Access to high-cost mental health medications. November 1999. Bazelon Center for the National Institute of Mental Health, Service Systems Research Program, 5600 Fishers Lane, Rockville, MD 20857 (contract number QVP-80076): http://www.bazelon.org/issues/medicaid/ publications/formulary.htm (accessed: 6/3/2004).
45. Stahl SM. Editorial: Antipsychotic polypharmacy: Evidence based or eminence based? Acta Psychiatr Scand 2002;106: 321-2.
46. Saxena S, Sharan P, Saraceno B. Budget and financing of mental health services: Baseline information on 89 countries from WHO's Project Atlas. JMent Health Policy Econ 2003; 6(3):135-43.
47. Launois R, Toumi M, Reboul-Marty J, Lancon C. Cost of illness: An inextricable maze or an aid in decision making? The case of schizophrenia] [in French]. Encephale 1998; 24(2):83-99.
48. Castle D, Morgan V, Jablensky A. Antipsychotic use in Australia: the patients' perspective. Aust NZ Psychiatry 2002;36(5):633-41.
49. McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry 2003;64(9):984-9.
50. Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project. Antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004;65: 500-8.